Entera Bio (ENTX)
(Delayed Data from NSDQ)
$1.80 USD
0.00 (0.00%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENTX 1.80 0.00(0.00%)
Will ENTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENTX
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Argenx (ARGX) This Year?
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Other News for ENTX
Stochastic Buy Signal appears for ENTX after 0.0% move
Technical picture remains unchanged for ENTX after it rises 1.69% on September 18
ENTX's price falls by 2.75% on September 18, though its technical setup remains stable.
Technical picture remains unchanged for ENTX after it falls 0.55% on September 16
Technical picture remains unchanged for ENTX after it rises 1.67% on September 15